| Pericellular fibrosis presence (N = 20) | Pericellular fibrosis absence (N = 25) | P value |
---|---|---|---|
AST (U/L) | 34.75 ± 25.06 | 22.62 ± 9.19 | 0.023 |
Males | 50.0% | 19.0% | 0.036 |
Females | 35.7% | 25% | NS |
Advanced fibrosis presence (Score ≥ 3) | 60% | 9.5% | 0.0006 |
NALP4 mRNA | 0.18 ± 0.20 | 1.12 ± 2.53 | 0.019 |
IL1B mRNA | 6.17 ± 12.05 | 14.96 ± 18.21 | 0.003 |
 | Portal fibrosis presence (N = 34) | Portal fibrosis absence (N = 11) | P value |
Advanced fibrosis presence (Score ≥ 3) | 45.2% | 0 | 0.008 |
NASH | 58.1% | 20% | 0.03 |
NALP6 mRNA | 0.86 ± 0.93 | 0.38 ± 0.38 | 0.028 |
IL-18 (pg/mL) | 390.95 pg/mL ± 176.84 | 246.08 pg/mL ± 103.10 | 0.022 |
 | NASH (N = 20) | Non-NASH NAFLD (N = 25) | P value |
Gender (Females) | 50% | 81% | < 0.036 |
Portal Fibrosis (presence) | 1.35 ± 0.67 | 0.71 ± 0.64 | < 0.005 |
Pericellular Fibrosis (presence) | 1.45 ± 0.60 | 0.05 ± 0.22 | < 0.001 |
Advanced fibrosis (Score ≥ 3) | 60% | 9.5% | < 0.0006 |
Degree of lobular inflammation | 2.55 ± 1.61 | 1.52 ± 0.98 | < 0.02 |
AST (U/L) | 35.70 ± 24.79 | 21.71 ± 8.52 | < 0.004 |
NALP 4 mRNA | 0.16 ± 0.19 | 1.14 ± 2.53 | < 0.002 |
NALP 5 mRNA | 0.14 ± 0.12 | 1.24 ± 2.58 | < 0.02 |
NALP 7 mRNA | 0.14 ± 0.12 | 1.09 ± 2.54 | < 0.03 |
NALP 8 mRNA | 0.14 ± 0.12 | 1.09 ± 2.54 | < 0.03 |
NALP 9 mRNA | 0.14 ± 0.12 | 1.25 ± 2.70 | < 0.03 |
NALP 10 mRNA | 0.14 ± 0.12 | 1.09 ± 2.54 | < 0.03 |
NALP 11 mRNA | 0.14 ± 0.12 | 1.09 ± 2.54 | < 0.02 |
NALP 13 mRNA | 0.14 ± 0.12 | 1.09 ± 2.54 | < 0.03 |
IL-1B mRNA | 8.71 ± 15.45 | 12.66 ± 16.68 | < 0.02 |